Akston Biosciences
  • Programs
    • Pipeline
    • Platform
    • Process
  • Company
    • Overview
    • Leadership
    • Facilities
    • Partners
    • Contact
  • Careers
    • Overview
    • Career Opportunities
    • Our Culture
    • Contact
  • News
    • Overview
    • In The News
    • Press Releases
    • Papers

Press Releases

8 March 2023

Akston Biosciences Ends Vaccine Partnership with Stelis, Continues to Advance COVID Universal Booster EUA

23 January 2023

Akston Biosciences Strengthens Board with Addition of John T. Preston

1 November 2022

Akston Biosciences Announces Positive Interim Phase II Results from COVID “Universal” Booster Vaccine Trial

9 August 2022

Akston Biosciences Receives U.S. Patent for Once-A-Week Human Insulin

24 June 2022

Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

12 May 2022

Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster

12 April 2022

Akston Biosciences CEO to Present at the World Vaccine Congress

7 April 2022

Akston Biosciences Doses First Volunteers in Phase II/III Clinical Trial of Low Cost, Shelf Stable COVID-19 Vaccine

31 March 2022

Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster

17 March 2022

Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries

Posts navigation

1 2 3 4 »

Akston BioSciences

info@akstonbio.com |

  • Home
  • Company
  • Pipeline
  • Careers
  • Press Releases
  • Contact

©2023 Akston Biosciences Corporation